Alphabet's GV Leads Funding in Gene Editing Company Verve Therapeutics
GV led a $58.5 million investment to launch Verve Therapeutics, a new biotech focused on developing therapies that edit the human genome to treat heart diseases.
from RSS Feeds | GOOGLE - RSS Feed - NDTV Gadgets360.com http://bit.ly/2DTO11A
from RSS Feeds | GOOGLE - RSS Feed - NDTV Gadgets360.com http://bit.ly/2DTO11A
Comments
Post a Comment